MAIN ARTICLE
Where AI saves time between data and molecules
Conventional drug discovery begins by asking which biological process can be changed to treat an illness. Scientists then identify targets, generate candidate compounds and test them repeatedly to discard molecules that are ineffective or unsafe. AI models can examine enormous collections of chemical, biological and experimental evidence, helping research teams rank candidates before committing laboratory resources. Connected to automated instruments, the systems can even recommend which experiment is most informative to conduct next.
This changes how researchers allocate scarce expertise. Instead of exhaustively testing every plausible option, they can use predictions to identify a manageable group for laboratory validation. AstraZeneca says AI now plays a role throughout its discovery-to-development pipeline. But a model's usefulness depends on the quality and relevance of its training data, and on independent experiments. A convincing computational prediction may still unravel in the complexity of a living human body.
What the drugmakers can demonstrate—and what they cannot
Novartis reports that the average interval from project launch to a drug candidate has declined from about three years to roughly 18 months to two years. Novo Nordisk says its design-make-test loops have dropped from around eight to three, while each loop has been cut from eight weeks to four.















